Photo from archive.org
Tuberculosis (TB) patients with multidrug-resistant (resistance to isoniazid and rifampicin) (MDR-TB) or rifampicin-resistant strains (MDR/RR-TB) do not respond to the standardised first-line TB regimen which is highly effective in other… Click to show full abstract
Tuberculosis (TB) patients with multidrug-resistant (resistance to isoniazid and rifampicin) (MDR-TB) or rifampicin-resistant strains (MDR/RR-TB) do not respond to the standardised first-line TB regimen which is highly effective in other TB patients, requiring much longer and toxic second-line treatment [1]. In fact, only about a half of all MDR/RR-TB patients placed on these regimens worldwide complete them successfully, attesting to the difficulties in scaling up such regimens satisfactorily [2]. Even if only about 4% of new TB patients globally have MDR/RR-TB, they account for over half a million new individuals annually, challenging the constrained resources available for TB care in the low- and middle-income countries where most of them live. Donor support of innovative interventions such as operational research can reap rapid benefits for TB control http://ow.ly/wcXM3091P9H
Journal Title: European Respiratory Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!